Studies report up to 18% (n/N = 9/49) of patients aged ≥60 years old with heart failure with preserved ejection fraction (HFpEF) had transthyretin amyloid cardiomyopathy (ATTR-CM), one of the main types of cardiac amyloidosis.¹ Clinical expert Dr Kate Gatenby highlights this and gives an overview of the causes, diagnosis and best practices in the management of patients with ATTR-CM.